A 3-period Double-blind, Cross-over Study on the Onset of Action of Inhaled Ciclesonide (7 Days of 400 mcg Sid Versus 800 mcg Bid Versus Placebo) on Airway Responsiveness to Adenosine Monophosphate (AMP), Sputum Eosinophiles and Exhaled Breath Nitric Oxide (NO) in Patients With Asthma
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Ciclesonide (Primary)
- Indications Asthma
- Focus Biomarker; Pharmacodynamics
- Sponsors Fougera Pharmaceuticals
- 30 Oct 2007 New trial record.